ProMIS Neurosciences PMN
NASDAQ PMN
$14.81 -0.10 (-0.64%)
As of: Aug 21, 2026 · 12:40 PM EDT

ProMIS Neurosciences (PMN) Total Non-Current Liabilities (2021 - 2025)

ProMIS Neurosciences' (PMN) quarterly Total Non-Current Liabilities came in at $10.4 million in Q4 2025, up 330.65% YoY from $2.4 million in Q4 2024, and down 15.11% on a QoQ basis from $12.3 million in Q3 2025.

ProMIS Neurosciences (PMN) Total Non-Current Liabilities (2021 - 2025) Analysis & Trends

ProMIS Neurosciences (PMN) has 5 years of Total Non-Current Liabilities data on file, last reported at $10.4 million in Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 330.65% year-over-year to $10.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.4 million (up 330.65% YoY) and the FY2025 annual result came in at $10.4 million, up 330.65% from the prior year.
  • Total Non-Current Liabilities eased to $10.4 million in Q4 2025, from $12.3 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $12.3 million in Q3 2025 to a low of $1.9 million in Q2 2022.
  • A 5-year average of $6.6 million and a median of $6.6 million in 2021 frame the typical range for Total Non-Current Liabilities.
  • Annual changes were most pronounced in 2023 — Total Non-Current Liabilities soared 366.31% — and 2024, when it tumbled 75.26%.
  • Tracing PMN's Total Non-Current Liabilities over 5 years: stood at $6.7 million in 2021, then slipped by 4.38% to $6.4 million in 2022, then jumped by 52.37% to $9.8 million in 2023, then plunged by 75.26% to $2.4 million in 2024, then soared by 330.65% to $10.4 million in 2025.
  • The last three Total Non-Current Liabilities figures came in at $10.4 million (Q4 2025), $12.3 million (Q3 2025), and $9.9 million (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 138.81 Bn 130.96 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 86.07 Bn 78.08 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 65.47 Bn 60.29 Bn 1.37 Bn 40.00 Mn
4 Moderna 55.64 Bn 50.50 Bn 52.00 Mn 3.92 Bn
5 BeOne Medicines 41.99 Bn 36.89 Bn 1.53 Bn 1.88 Bn
6 Alnylam Pharmaceuticals 31.68 Bn 28.37 Bn 992.69 Mn 4.20 Bn
7 BioNTech SE 27.69 Bn 9.29 Bn 668.28 Mn 724.15 Mn
8 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 1.17 Bn
9 Royalty Pharma 27.36 Bn 26.52 Bn - 9.32 Bn
10 ProMIS Neurosciences 135.44 Mn 81.98 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 10.41 Mn
Sep 30, 2025 12.27 Mn
Jun 30, 2025 9.89 Mn
Mar 31, 2025 4.17 Mn
Dec 31, 2024 2.42 Mn
Sep 30, 2024 2.98 Mn
Jun 30, 2024 3.64 Mn
Mar 31, 2024 3.36 Mn
Dec 31, 2023 9.77 Mn
Sep 30, 2023 10.84 Mn
Jun 30, 2023 8.74 Mn
Mar 31, 2023 8.71 Mn
Dec 31, 2022 6.41 Mn
Sep 30, 2022 3.10 Mn
Jun 30, 2022 1.87 Mn
Dec 31, 2021 6.71 Mn